Lindsay A Renfro1, Fotios Loupakis2, Richard A Adams2, Matthew T Seymour2, Volker Heinemann2, Hans-Joachim Schmoll2, Jean-Yves Douillard2, Herbert Hurwitz2, Charles S Fuchs2, Eduardo Diaz-Rubio2, Rainer Porschen2, Christophe Tournigand2, Benoist Chibaudel2, Alfredo Falcone2, Niall C Tebbutt2, Cornelis J A Punt2, J Randolph Hecht2, Carsten Bokemeyer2, Eric Van Cutsem2, Richard M Goldberg2, Leonard B Saltz2, Aimery de Gramont2, Daniel J Sargent2, Heinz-Josef Lenz2. 1. Lindsay A. Renfro and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Fotios Loupakis and Alfredo Falcone, Azienda Ospedaliero-Universitaria Pisana and Università di Pisa, Pisa, Italy; Richard Adams, Cardiff University, Cardiff; Matthew T. Seymour, St James's Hospital and University of Leeds, Leeds, United Kingdom; Volker Heinemann, University of Munich, Munich; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle; Rainer Porschen, Klinikum Bremen-Ost Klinik für Innere Medizin, Bremen; Carsten Bokemeyer, University Hospital Cancer Center, University Hospital, Hamburg-Eppendorf, Germany; Jean-Yves Douillard, Institut de Cancerologie, Centre René Gauducheau, Nantes; Christophe Tournigand, University of Paris Est Creteil, Henri-Mondor Hospital, Créteil; Benoist Chibaudel and Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Charles S. Fuchs, Dana-Farber Cancer Institute Boston, MA; Eduardo Diaz-Rubio, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia; Cornelis J.A. Punt, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; J. Randolph Hecht, David Geffen School of Medicine at the University of California at Los Angeles; Heinz-Josef Lenz, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; Richard M. Goldberg, Ohio State University, Columbus, OH; and Leonard B. Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY. renfro.lindsay@mayo.edu. 2. Lindsay A. Renfro and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Fotios Loupakis and Alfredo Falcone, Azienda Ospedaliero-Universitaria Pisana and Università di Pisa, Pisa, Italy; Richard Adams, Cardiff University, Cardiff; Matthew T. Seymour, St James's Hospital and University of Leeds, Leeds, United Kingdom; Volker Heinemann, University of Munich, Munich; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle; Rainer Porschen, Klinikum Bremen-Ost Klinik für Innere Medizin, Bremen; Carsten Bokemeyer, University Hospital Cancer Center, University Hospital, Hamburg-Eppendorf, Germany; Jean-Yves Douillard, Institut de Cancerologie, Centre René Gauducheau, Nantes; Christophe Tournigand, University of Paris Est Creteil, Henri-Mondor Hospital, Créteil; Benoist Chibaudel and Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Charles S. Fuchs, Dana-Farber Cancer Institute Boston, MA; Eduardo Diaz-Rubio, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia; Cornelis J.A. Punt, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; J. Randolph Hecht, David Geffen School of Medicine at the University of California at Los Angeles; Heinz-Josef Lenz, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; Richard M. Goldberg, Ohio State University, Columbus, OH; and Leonard B. Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract
PURPOSE: In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear. PATIENTS AND METHODS: Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted). RESULTS: BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m(2), and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m(2) had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect. CONCLUSION: Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.
PURPOSE: In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear. PATIENTS AND METHODS: Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted). RESULTS: BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m(2), and then it plateaued. Relative to obesepatients, patients with a BMI of 18.5 kg/m(2) had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect. CONCLUSION: Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.
Authors: Aimery de Gramont; Daniel G Haller; Daniel J Sargent; Josep Tabernero; Alastair Matheson; Richard L Schilsky Journal: J Clin Oncol Date: 2009-10-19 Impact factor: 44.544
Authors: Frank A Sinicrope; Nathan R Foster; Daniel J Sargent; Michael J O'Connell; Cathryn Rankin Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Qian Shi; Aimery de Gramont; Axel Grothey; John Zalcberg; Benoist Chibaudel; Hans-Joachim Schmoll; Matthew T Seymour; Richard Adams; Leonard Saltz; Richard M Goldberg; Cornelis J A Punt; Jean-Yves Douillard; Paulo M Hoff; Joel Randolph Hecht; Herbert Hurwitz; Eduardo Díaz-Rubio; Rainer Porschen; Niall C Tebbutt; Charles Fuchs; John Souglakos; Alfredo Falcone; Christophe Tournigand; Fairooz F Kabbinavar; Volker Heinemann; Eric Van Cutsem; Carsten Bokemeyer; Marc Buyse; Daniel J Sargent Journal: J Clin Oncol Date: 2014-11-10 Impact factor: 44.544
Authors: James J Dignam; Blase N Polite; Greg Yothers; Peter Raich; Linda Colangelo; Michael J O'Connell; Norman Wolmark Journal: J Natl Cancer Inst Date: 2006-11-15 Impact factor: 13.506
Authors: Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Andrew Hendifar; Dongyun Yang; Felicitas Lenz; Georg Lurje; Alexandra Pohl; Cosima Lenz; Yan Ning; Wu Zhang; Heinz-Josef Lenz Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Jessica R Lieffers; Marina Mourtzakis; Kevin D Hall; Linda J McCargar; Carla M M Prado; Vickie E Baracos Journal: Am J Clin Nutr Date: 2009-02-25 Impact factor: 7.045
Authors: Laurence Albiges; A Ari Hakimi; Wanling Xie; Rana R McKay; Ronit Simantov; Xun Lin; Jae-Lyun Lee; Brian I Rini; Sandy Srinivas; Georg A Bjarnason; Scott Ernst; Lori A Wood; Ulka N Vaishamayan; Sun-Young Rha; Neeraj Agarwal; Takeshi Yuasa; Sumanta K Pal; Aristotelis Bamias; Emily C Zabor; Anders J Skanderup; Helena Furberg; Andre P Fay; Guillermo de Velasco; Mark A Preston; Kathryn M Wilson; Eunyoung Cho; David F McDermott; Sabina Signoretti; Daniel Y C Heng; Toni K Choueiri Journal: J Clin Oncol Date: 2016-10-20 Impact factor: 44.544
Authors: Justin C Brown; Bette J Caan; Carla M Prado; Elizabeth M Cespedes Feliciano; Jingjie Xiao; Candyce H Kroenke; Jeffrey A Meyerhardt Journal: J Natl Cancer Inst Date: 2020-04-01 Impact factor: 13.506
Authors: Katrin M Sjoquist; Lindsay A Renfro; R John Simes; Niall C Tebbutt; Stephen Clarke; Matthew T Seymour; Richard Adams; Timothy S Maughan; Leonard Saltz; Richard M Goldberg; Hans-Joachim Schmoll; Eric Van Cutsem; Jean-Yves Douillard; Paulo M Hoff; Joel Randolph Hecht; Christophe Tournigand; Cornelis J A Punt; Miriam Koopman; Herbert Hurwitz; Volker Heinemann; Alfredo Falcone; Rainer Porschen; Charles Fuchs; Eduardo Diaz-Rubio; Enrique Aranda; Carsten Bokemeyer; Ioannis Souglakos; Fairooz F Kabbinavar; Benoist Chibaudel; Jeffrey P Meyers; Daniel J Sargent; Aimery de Gramont; John R Zalcberg Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Lindsay A Renfro; Richard M Goldberg; Axel Grothey; Alberto Sobrero; Richard Adams; Matthew T Seymour; Volker Heinemann; Hans-Joachim Schmoll; Jean-Yves Douillard; Herbert Hurwitz; Charles S Fuchs; Eduardo Diaz-Rubio; Rainer Porschen; Christophe Tournigand; Benoist Chibaudel; Paulo M Hoff; Fairooz F Kabbinavar; Alfredo Falcone; Niall C Tebbutt; Cornelis J A Punt; J Randolph Hecht; John Souglakos; Carsten Bokemeyer; Eric Van Cutsem; Leonard Saltz; Aimery de Gramont; Daniel J Sargent Journal: J Clin Oncol Date: 2017-04-17 Impact factor: 44.544